Physician profile
Cecelia Pyc
NPI 1336826791
$3,448.55
in general payments reported to CMS, 2019-2025
23 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $805 · 2024: $1,599 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,294 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.57 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $510.70 | 2024-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $500.17 | 2023-2025 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $483.05 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.54 | 2023-2025 | Jardiance, Cyltezo, Ofev |
| Ucb, INC. | $255.43 | 2023-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $245.29 | 2024-2025 | |
| Edwards Lifesciences Corporation | $175.37 | 2025 | |
| Pfizer INC. | $156.52 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $113.34 | 2023-2025 | Saphnelo, Farxiga |
| Mallinckrodt Hospital Products INC. | $111.85 | 2023-2024 | Acthar |
| Lilly USA, LLC | $110.62 | 2023-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $109.76 | 2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $89.71 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $48.31 | 2025 | Camzyos, Eliquis |
| Horizon Therapeutics Plc | $43.43 | 2023 | Krystexxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.30 | 2024-2025 | Benlysta, Nucala |
| Actelion Pharmaceuticals US, INC. | $28.42 | 2023 | Opsumit |
| Pharmacosmos Therapeutics INC. | $27.12 | 2025 | Monoferric |
| Scpharmaceuticals INC. | $22.18 | 2025 | |
| Merck Sharp & Dohme LLC | $21.23 | 2025 | Verquvo |
| Bridgebio Pharma, INC. | $19.22 | 2025 | Attruby |
| Organon LLC | $17.98 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecelia Pyc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.